Oncology Research Highlights

A focused selection of studies that connect biomedical questions, clinical data and credible evidence.

Current selection: 10 November 20263 studies · peer-reviewedGenMabs editorial perspective

What deserves
a closer look?

We select research for its scientific question, evidence and relevance to biomedical teams. The summaries describe the authors’ work; the GenMabs perspective identifies questions for study design, interpretation and future evaluation. Current highlights are a curated selection, not a claim that every paper was first published this week.

01

Single-cell evidence and TM4SF1 in LUAD prognostic modeling

Li and colleagues · Frontiers in Oncology · 6 November 2026

The research

Li and colleagues investigated lung adenocarcinoma using single-cell transcriptomic evidence and developed a prognostic signature using StepCox-forward and ridge-based modeling. TM4SF1 emerged as a candidate associated with malignant progression, alongside analyses of the tumor immune microenvironment and immune-related markers.

GenMabs perspective

Biological plausibility and prediction performance should be evaluated separately. For a clinically useful LUAD survival model, assess the stability of feature selection, incremental discrimination beyond established clinical factors, calibration, and transportability to independent cohorts.

Evidence to keep in view. Associations and model development do not demonstrate that TM4SF1 is a causal driver or a clinically actionable marker. The evidence for external validation and prospective decision impact must be assessed before clinical-use claims.

02

Beyond histologic subtype: biomarkers of lung cancer immunotherapy response

Gobbini and colleagues · Cancer Immunology Research · Online September 2026 (November issue)

The research

Gobbini and colleagues review biomarker evidence across lung cancer subtypes, including PD-L1, tumor mutational burden, microsatellite instability, antigen presentation, T-cell biology, and inflammatory signaling. The paper synthesizes possible shared mechanisms of immunotherapy response rather than reporting a newly validated patient-level prediction model.

GenMabs perspective

A biomarker that correlates with outcome among immunotherapy recipients is not automatically predictive of treatment benefit. Evaluation should distinguish prognostic associations from treatment-by-biomarker interactions and account for assay, population, and treatment-regimen differences.

Evidence to keep in view. This is a peer-reviewed review, not original external validation of a subtype-agnostic clinical test. Although appearing in a November 2026 issue, it was published online in September 2026 and should not be presented as a newly released November study.

03

Integrating clinical and molecular markers for immunotherapy response prediction

Yuan and colleagues · Journal of Cancer Research and Clinical Oncology · 16 September 2026

The research

Yuan and colleagues analyzed 342 patients with advanced lung cancer and developed a random-forest model combining clinical, immune, inflammatory, and molecular measurements to predict immunotherapy response. Reported AUCs were approximately 0.835 in training and 0.832 in a randomly split validation set.

GenMabs perspective

A high internal-split AUC is encouraging but is not equivalent to external clinical validation. For deployment, examine missingness, measurement timing, calibration, decision thresholds, and whether the model adds value over simpler clinical and PD-L1-based baselines.

Evidence to keep in view. The September 2026 study is not a newly published November paper. A single-cohort random split may overstate generalizability; the reported marker integration should not be conflated with complete DNA–RNA–protein multiomics or with prospective treatment-benefit estimation.

Current selection curated 10 November 2026; archive selection reviewed 29 October 2026. Online publication dates and source status are shown for each entry. Original summaries and editorial interpretation by GenMabs; research findings remain attributable to their authors. Preprints in the archive have not completed peer review.

Questions behind the analysis

Research feasibility, endpoint selection and the connection between biology and measurement are central to meaningful analysis.

Explore scientific consulting →

Discoveries with a lasting influence

Explore the experimental ideas and biological mechanisms behind selected Nobel-recognised milestones.

Explore the milestones →